CPC-105 Pharmacoeconomic Aspects of the Treatment of Rheumatoid Arthritis with Tumour Necrosis Facto...
CPC-105 Pharmacoeconomic Aspects of the Treatment of Rheumatoid Arthritis with Tumour Necrosis Factor Alpha Antagonists: A Societal Perspective
About this item
Full title
Author / Creator
Marongiu, C , Francisco, C , Modena, V , Azzolini, V , Milla, P and Cattel, L
Publisher
London: BMJ Publishing Group LTD
Journal title
Language
English
Formats
Publication information
Publisher
London: BMJ Publishing Group LTD
Subjects
More information
Scope and Contents
Contents
Background Rheumatoid arthritis (RA) is an autoimmune disorder, affecting 1% of the population, characterised by pain, joint swelling and progressive destruction of joint tissue. EULAR (European League Against Rheumatism) recommends the use of Tumour Necrosis Factor alpha antagonists (anti-TNFα) if methotrexate or Disease Modifying Antirheumatic Dr...
Alternative Titles
Full title
CPC-105 Pharmacoeconomic Aspects of the Treatment of Rheumatoid Arthritis with Tumour Necrosis Factor Alpha Antagonists: A Societal Perspective
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_2552756511
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2552756511
Other Identifiers
ISSN
2047-9956
E-ISSN
2047-9964
DOI
10.1136/ejhpharm-2013-000276.562
